Global Polycystic Kidney Disease (PKD) Market, By Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
Polycystic Kidney Disease (PKD) Market Analysis and Size
In recent years, the global polycystic kidney disease (PKD) market is anticipated to grow rapidly during the forecast period of 2023 to 2030, owing to the rising prevalence of kidney disorders. Polycystic kidney disease is caused by genetic abnormalities. In the majority of cases, the disorder is passed down to the children by their parents. As a result, you are born with PKD. However, genes can mutate or change at any time.
Data Bridge Market Research analyzes that the global polycystic kidney disease (PKD) market which was USD 0.49 billion in 2022, is expected to reach USD 0.77 billion by 2030, and is expected to undergo a CAGR of 5.8% during the forecast period 2023 to 2030. “Autosomal Dominant Polycystic Kidney Disease” dominates the type segment of the global polycystic kidney disease (PKD) market owing to the increasing prevalence of thalassemia. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Polycystic Kidney Disease (PKD) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Autosomal Dominant Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Others), Treatment (Medication, Surgery, Others), Diagnosis (Ultrasound, CT Scan, MRI Scan), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
Johnson & Johnson Services Inc. (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U S.), GSK plc (U.K.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Taro Pharmaceutical Industries Ltd. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), CorePharma LLC (U.S.), Hikma Pharmaceuticals Plc (U.K.), Kadmon Holdings Inc. (U.S.), Reata Pharmaceuticals Inc. (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (UK)
|
|
Market Opportunities
|
|
Market Definition
The genetic ailment polycystic kidney disease (PKD) causes cysts to form in the kidneys, causing them to malfunction. High blood pressure and renal failure are two health problems. PKD is a kind of chronic kidney disease that is very dangerous. Cysts can enlarge the kidneys, making it difficult for them to filter waste from the blood.
Global Polycystic Kidney Disease (PKD) Market Dynamics
Drivers
- Increasing Incidences of Kidney Failure
The global polycystic kidney disease (PKD) market is driven by an increase in incidences of renal failure or dialysis. Polycystic kidney disease can be caused by a number of factors, including a family history of kidney problems, a rare genetic mutation, kidney failure, or people on dialysis, all of which will raise the global polycystic kidney disease (PKD) market.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of global polycystic kidney disease (PKD) market is the rising healthcare expenditure which helps in improving its infrastructure. Furthermore, rising initiatives by public and private organizations to spread awareness will expand the global polycystic kidney disease (PKD) market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of global polycystic kidney disease (PKD) market. Along with this, favourable government policies and rising awareness about genetic diseases among people will enhance the growth rate of the market.
Opportunity
- Increase in the number of Research and Development Activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global polycystic kidney disease (PKD) market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the global polycystic kidney disease (PKD) market growth during the forecast period.
Restraint/Challenge
- High Cost associated with the Treatment of Polycystic Kidney Disease (PKD)
On the other hand, the high cost associated with the treatment of polycystic kidney disease (PKD) will obstruct the growth rate of global market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the global polycystic kidney disease (PKD) market. In addition, impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2023 to 2030.
This global polycystic kidney disease (PKD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the surgical microscopes market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Development
- In May 2023, a new Monash biotech business won money to slow the growth of polycystic kidney disease. Cystence Bio, a new Monash biotech business, has secured funding to accelerate research into novel therapies for polycystic kidney disease (PKD), a family of hereditary illnesses characterized by the formation of many large cysts in the kidneys
Global Polycystic Kidney Disease (Pkd) Market Scope
The global polycystic kidney disease (PKD) market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Autosomal Dominant Polycystic Kidney Disease
- Autosomal Recessive Polycystic Kidney Disease
- Others
Treatment
- Medication
- Surgery
- Others
Diagnosis
- Ultrasound
- CT Scan
- MRI Scan
Route Of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospital
- Speciality Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Global Polycystic Kidney Disease (PKD) Market Regional Analysis/Insights
The global polycystic kidney disease (PKD) market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global polycystic kidney disease (PKD) market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the global polycystic kidney disease (PKD) market because of the increasing healthcare initiatives, the strong presence of major players in the market, increasing cases of kidney diseases and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth in the global polycystic kidney (PKD) market, during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global polycystic kidney disease (PKD) market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global polycystic kidney disease (PKD) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global polycystic kidney disease (PKD) market. The data is available for the historic period 2015-2020.
Competitive Landscape and Global Polycystic Kidney Disease (PKD) Market Share Analysis
The global polycystic kidney disease (PKD) market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the global polycystic kidney disease (PKD) market are:
- Johnson & Johnson Services Inc. (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- AbbVie Inc. (U.S.)
- Novartis AG (Switzerland)
- Eli Lilly and Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co., Inc. (U.S.)
- Taro Pharmaceutical Industries Ltd. (U.S.)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- CorePharma LLC (U.S.)
- Hikma Pharmaceuticals Plc (U.K.)
- Kadmon Holdings Inc. (U.S.)
- Reata Pharmaceuticals Inc. (U.S.)
- AstraZeneca (U.K.)
SKU-